Rankings
▼
Calendar
KYMR Q1 2025 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
KYMR
Kymera Therapeutics, Inc.
$7B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$22M
+114.8% YoY
Gross Profit
$22M
100.0% margin
Operating Income
-$74M
-336.8% margin
Net Income
-$66M
-296.7% margin
EPS (Diluted)
$-0.82
QoQ Revenue Growth
+198.9%
Cash Flow
Operating Cash Flow
-$79M
Free Cash Flow
-$80M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$918M
Total Liabilities
$132M
Stockholders' Equity
$786M
Cash & Equivalents
$90M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$22M
$10M
+114.8%
Gross Profit
$22M
$10M
+114.8%
Operating Income
-$74M
-$58M
-28.7%
Net Income
-$66M
-$49M
-35.1%
← FY 2025
All Quarters
Q2 2025 →